CD192 (CCR2) Antibody, anti-human, REAfinity™

Name: CD192 (CCR2) Antibody, anti-human, REAfinity™
Availability: InStock

CD192 (CCR2) Antibody, anti-human, REAfinity™Extended ValidationRecombinant

Clone:

REA624

Type of antibody:

Primary antibodies, Recombinant antibodies

Isotype:

recombinant human IgG1

Applications:

FC

Alternative names:

C-C chemokine receptor type 2, C-C CKR-2, CC-CKR-2, CCR-2, Monocyte chemoattractant protein 1 receptor, MCP-1-R, MCP-1R

Flow cytometry applications forCD192 (CCR2) Antibody, anti-human, REAfinity™

APC
APC-Vio 770
Biotin
PE
PE-Vio 615
PE-Vio 770
Vio Bright FITC
Vio Bright V423

Conjugate:

APC

Recommended dilution:

1:11

Remark:

The antibody is suited for staining of formaldehyde-fixed cells.

Tested:

QC tested

Products used:

130-109-655, 130-109-596

Protocols:

Cell surface flow cytometry staining protocol for CCRs (1:11)

Description:

Human peripheral blood mononuclear cells (PBMCs) were stained with CD192 (CCR2) antibodies or with the corresponding REA Control (S) antibodies (left image) as well as with CD14 antibodies. Flow cytometry was performed using the MACSQuant^® Analyzer. The Tandem Signal Enhancer has been used to increase binding specificity of tandem-dye–conjugated antibodies. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence or 4',6-diamidino-2-phenylindole (DAPI) fluorescence, as in the case of tandem conjugates.

Extended validation for CD192 (CCR2) Antibody, anti-human, REAfinity™

Specificity

Epitope competition

In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.

Other clones	Overlap in epitope recognition with REA624
REA264	++
K03602	++
48607	++
Cells were incubated with an excess of purified unconjugated CD192 (CCR2) (REA624) antibody followed by staining with fluorochrome-conjugated antibodies of other known clones against the same marker. Based on the fluorescence signal obtained, the clones were identified as recognizing completely overlapping (++), partially overlapping (+), or completely different epitopes (-) of the marker.

Sensitivity

Performance comparison

Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.

Flow cytometric comparison of different clones for CD192 (CCR2). Human peripheral blood mononuclear cells (PBMCs) were stained with CD192 (CCR2) antibodies and with a suitable counterstaining. As a control, CD192 (CCR2) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant^® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Flow cytometric comparison of different clones for CD192 (CCR2). Human peripheral blood mononuclear cells (PBMCs) were stained with CD192 (CCR2) antibodies and with a suitable counterstaining. As a control, CD192 (CCR2) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant^® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Flow cytometric comparison of different clones for CD192 (CCR2). Human peripheral blood mononuclear cells (PBMCs) were stained with CD192 (CCR2) antibodies and with a suitable counterstaining. As a control, CD192 (CCR2) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant^® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Flow cytometric comparison of different clones for CD192 (CCR2). Human peripheral blood mononuclear cells (PBMCs) were stained with CD192 (CCR2) antibodies and with a suitable counterstaining. As a control, CD192 (CCR2) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant^® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Fixation data

To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.

No fixation

Post fixation

Comparison of staining pattern on non-fixed and fixed cells using CD192 (CCR2) (REA624). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Comparison of staining pattern on non-fixed and fixed cells using CD192 (CCR2) (REA624). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CD192 (CCR2) Antibody, anti-human, REAfinity™

Overview

Clone REA624 recognizes the CD192 antigen, a G protein–linked seven transmembrane receptor, which is also known as C-C chemokine receptor type 2 (CCR2) or monocyte chemoattractant protein 1 receptor (MCP-1-R). Two spliced variants of CD192 (CD192A and CD192B) are expressed on peripheral monocytes and basophils as a result of alternate splicing of a single gene and differ at the C-terminal end. CD192 and its main ligand CCL2 have been implicated in a wide range of immunobiological processes and neuropathologies, including recruitment of monocytes and regulation of bone marrow homeostasis, as well as multiple sclerosis, HIV-associated dementia, Alzheimer’s disease, and neuropathic pain.

Additional information: Clone REA624 displays negligible binding to Fc receptors.

Alternative names

C-C chemokine receptor type 2, C-C CKR-2, CC-CKR-2, CCR-2, Monocyte chemoattractant protein 1 receptor, MCP-1-R, MCP-1R

Detailed product information

Technical specifications

Clone	REA624
Clonality	monoclonal
Isotype	recombinant human IgG1
Isotype control	REA Control Antibody (S), human IgG1
Host	human cell line
Type of antibody	Primary antibodies, Recombinant antibodies
Species	human
Antigen	CD192 (CCR2)
Alternative names of antigen	C-C chemokine receptor type 2, C-C CKR-2, CC-CKR-2, CCR-2, Monocyte chemoattractant protein 1 receptor, MCP-1-R, MCP-1R
Molecular mass of antigen [kDa]	42
Distribution of antigen	monocytes, basophils
Entrez Gene ID	1231
RRID	AB_2904792, AB_2655866, AB_2655867, AB_2655868, AB_2655869, AB_2655870, AB_2655871, AB_2655872, AB_2655873, AB_2655874, AB_2655875, AB_2928300, AB_2928299, AB_2928302, AB_2928301, AB_2904793

Resources for CD192 (CCR2) Antibody, anti-human, REAfinity™

Certificates

Please follow this

link

to search for Certificates of Analysis (CoA) by lot number.

References for CD192 (CCR2) Antibody, anti-human, REAfinity™

Publications

Charo, I. F. et al. (1994) Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails. Proc. Natl. Acad. Sci. U.S.A. 91(7): 2752-2756
Wong, L. M. et al. (1997) Organization and differential expression of the human monocyte chemoattractant protein 1 receptor gene. Evidence for the role of the carboxyl-terminal tail in receptor trafficking. J. Biol. Chem. 272(2): 1038-1045
Henrich, T. J. et al. (2013) HIV-1 entry inhibitors: recent development and clinical use. Curr. Opin. Virol. 3(1): 51-57

Applications

Extended validation